Alternatives routes of insulin delivery.

Optimal glycaemic control is necessary to prevent diabetes-related complications. An intensive treatment, which could mimic physiological insulin secretion, would be the best one. However subcutaneous insulin treatment is not physiologic and represents a heavy burden for patients with type 1 and type 2 diabetes mellitus. Consequently, more acceptable, at least as effective, alternative routes of insulin delivery have been developed over the past years. Up to now, only pulmonary administration of insulin (inhaled insulin) has become a feasible alternative to cover mealtime insulin requirements and one of the various administration systems was recently approved for clinical use in Europe and the United States. But, due to advances in technology, other routes, such as transdermal or oral (buccal and intestinal) insulin administration, could become feasible in a near future, and they could be combined together to offer non-invasive, efficacious and more physiological way of insulin administration to patients with diabetes.

[1]  M. Foldvari,et al.  Evidence for lymphatic transport of insulin by topically applied biphasic vesicles , 2003, The Journal of pharmacy and pharmacology.

[2]  Y. Miyazaki,et al.  Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects. , 2004, Diabetes care.

[3]  B. Aungst Site-dependence and structure-effect relationships for alkylglycosides as transmucosal absorption promoters for insulin , 1994 .

[4]  Nick Freemantle,et al.  Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. , 2005, Diabetes care.

[5]  J. Manson,et al.  Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes. , 1985 .

[6]  L. Machet,et al.  Phonophoresis: efficiency, mechanisms and skin tolerance. , 2002, International journal of pharmaceutics.

[7]  M. Singh,et al.  Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery. , 2000, Current medicinal chemistry.

[8]  Jim Wright,et al.  Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[9]  M. Kisel,et al.  Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. , 2001, International journal of pharmaceutics.

[10]  R. Greenwood,et al.  Buccal administration of human insulin in streptozocin-diabetic rats. , 1993, Research communications in chemical pathology and pharmacology.

[11]  I. Kwon,et al.  Self-assembled “nanocubicle” as a carrier for peroral insulin delivery , 2002, Diabetologia.

[12]  J. Hadgraft,et al.  Modulation of the Barrier Function of the Skin , 2001, Skin Pharmacology and Physiology.

[13]  P. Maincent,et al.  Formulation of Insulin-Loaded Polymeric Nanoparticles Using Response Surface Methodology , 2005, Drug development and industrial pharmacy.

[14]  B. Aungst,et al.  Site Dependence of Absorption-Promoting Actions of Laureth-9, Na Salicylate, Na2EDTA, and Aprotinin on Rectal, Nasal, and Buccal Insulin Delivery , 1988, Pharmaceutical Research.

[15]  S. Mudaliar,et al.  Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. , 2003, Diabetes care.

[16]  G. Cevc Transdermal Drug Delivery of Insulin with Ultradeformable Carriers , 2003, Clinical pharmacokinetics.

[17]  L. Heinemann,et al.  Inhaled micronized crystalline human insulin using a dry powder inhaler: dose‐response and time‐action profiles 1 , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[18]  S. Davis,et al.  Intranasal Insulin , 1992, Clinical pharmacokinetics.

[19]  J. Pickup Biotechnology of insulin therapy , 1991 .

[20]  F. Patat,et al.  Effect of sonication parameters on transdermal delivery of insulin to hairless rats. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Michael Yianneskis,et al.  Drug delivery to the respiratory tract using dry powder inhalers , 1994 .

[22]  S. Fineberg,et al.  Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. , 2005, The Journal of clinical endocrinology and metabolism.

[23]  S. Mudaliar,et al.  Young and Elderly Type 2 Diabetic Patients Inhaling Insulin with the AERx® Insulin Diabetes Management System: A Pharmacokinetic and Pharmacodynamic Comparison , 2003, Journal of clinical pharmacology.

[24]  Qiang Zhang,et al.  Sublingual delivery of insulin: effects of enhancers on the mucosal lipid fluidity and protein conformation, transport, and in vivo hypoglycemic activity. , 2005, Biological & pharmaceutical bulletin.

[25]  A. Barnett,et al.  Inhaled insulin: new technology, new possibilities , 2006, International journal of clinical practice.

[26]  R. Becker,et al.  The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. , 2006, Diabetes care.

[27]  S. Fineberg Diabetes therapy trials with inhaled insulin , 2006, Expert opinion on investigational drugs.

[28]  W. Cefalu,et al.  Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.

[29]  Donald E. Chickering,et al.  Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.

[30]  B. W. Barry,et al.  Novel mechanisms and devices to enable successful transdermal drug delivery. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[31]  M. Aprahamian,et al.  Ileal Uptake of Polyalkylcyanoacrylate Nanocapsules in the Rat , 2000, The Journal of pharmacy and pharmacology.

[32]  J. Varshosaz,et al.  Nasal Delivery of Insulin Using Bioadhesive Chitosan Gels , 2006, Drug delivery.

[33]  W. Ritschel,et al.  Absorption characteristics of insulin through the buccal mucosa. , 1990, Methods and Findings in Experimental and Clinical Pharmacology.

[34]  V. Lassmann-Vague [Unusual ways of insulin administration]. , 1988, Diabete & metabolisme.

[35]  A. Pfützner,et al.  Technosphere/Insulin--a new approach for effective delivery of human insulin via the pulmonary route. , 2002, Diabetes technology & therapeutics.

[36]  T. Heise,et al.  Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. , 2004, Diabetes technology & therapeutics.

[37]  S. Madsbad,et al.  Intranasal insulin therapy: the clinical realities , 1995, Diabetologia.

[38]  I. Raz,et al.  Dose-response relationship of oral insulin spray in healthy subjects. , 2005, Diabetes care.

[39]  I. Raz,et al.  Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. , 2005, Clinical therapeutics.

[40]  G. Slama,et al.  Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic Type 2 diabetic patients with oral drug failure: a cross‐over study , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[41]  J. Guevara-Aguirre,et al.  Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study , 2004, Diabetes/metabolism research and reviews.

[42]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[43]  W. Cefalu,et al.  Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study , 2001, The Lancet.

[44]  C. Dunn,et al.  Inhaled human insulin (Exubera): a review of its use in adult patients with diabetes mellitus. , 2006, Drugs.

[45]  R. DeFronzo,et al.  Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. , 2005, Diabetes care.

[46]  Lawrence Blonde,et al.  Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. , 2004, Diabetes care.

[47]  Y. Kalia,et al.  Non‐invasive assessment of the effects of iontophoresis on human skin in‐vivo , 2001, The Journal of pharmacy and pharmacology.

[48]  J. Rosenstock,et al.  Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes , 2006, Diabetologia.

[49]  J. Still Development of oral insulin: progress and current status. , 2002 .

[50]  J. Patton,et al.  Mechanisms of macromolecule absorption by the lungs , 1996 .

[51]  Joseph C Cappelleri,et al.  Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. , 2004, Diabetes care.

[52]  L. Heinemann,et al.  Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. , 2005, Diabetes care.

[53]  M. Ellmerer,et al.  Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients , 2001, Diabetologia.

[54]  J. Brand,et al.  LACTOSE INTOLERANCE AND YOGHURT , 1980, The Lancet.

[55]  S. Mitragotri,et al.  Low-frequency sonophoresis: a review. , 2004, Advanced drug delivery reviews.

[56]  P. Raskin,et al.  Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. , 2005, Diabetes care.

[57]  B. Buckley,et al.  Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with type 1 diabetes: a preliminary study. , 2006, Diabetes technology & therapeutics.

[58]  Bernard Lennox,et al.  NORMALISATION: A POSSIBLE GENERAL SOLUTION TO THE UNITS PROBLEM , 1975, The Lancet.

[59]  P. Byron Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. , 1986, Journal of pharmaceutical sciences.

[60]  T. Quattrin,et al.  Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. , 2004, Diabetes care.

[61]  B. Zinman,et al.  Alternative routes of insulin delivery , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[62]  A. McElduff,et al.  Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. , 2000, Diabetes technology & therapeutics.

[63]  T. Rönnemaa,et al.  Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. , 2004, Diabetes care.

[64]  P. Kam,et al.  Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System. , 2005, British journal of clinical pharmacology.

[65]  N. Freemantle,et al.  Will availability of inhaled human insulin (Exubera®) improve management of type 2 diabetes? The design of the Real World trial , 2006, Trials.

[66]  Biana Godin,et al.  Ethosomes: new prospects in transdermal delivery. , 2003, Critical reviews in therapeutic drug carrier systems.

[67]  A. Turner-Henson,et al.  Insulin administration to the eyes of normoglycemic human volunteers. , 1994, Journal of ocular pharmacology.

[68]  R. V. Morgan,et al.  Delivery of systemic regular insulin via the ocular route in dogs. , 1996, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[69]  R. Reinhardt,et al.  Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. , 2003, Clinical therapeutics.

[70]  J. Hankiss Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects. , 1982, British medical journal.

[71]  G. Slama,et al.  Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local tolerance. , 2001, Diabetes & metabolism.

[72]  G. Jerums,et al.  Long-Term Use of Intranasal Insulin in Insulin-Dependent Diabetic Patients , 1987, Diabetes Care.

[73]  Carino,et al.  Oral insulin delivery. , 1999, Advanced drug delivery reviews.

[74]  Jeff Schuster,et al.  The AERX™ Aerosol Delivery System , 1997, Pharmaceutical Research.

[75]  G. Schellenberg,et al.  Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype , 2006, Neurobiology of Aging.

[76]  Y. Kalia,et al.  Factors and strategies for improving buccal absorption of peptides. , 2001, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[77]  A. Fernandez-cruz,et al.  Changes in the density and localisation of endothelin receptors in the early stages of rat diabetic retinopathy and the effect of insulin treatment , 2000, Diabetologia.

[78]  M. Kipnes,et al.  Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. , 2003, Diabetes care.

[79]  Adrian C. Williams,et al.  Can drug‐bearing liposomes penetrate intact skin? , 2006, The Journal of pharmacy and pharmacology.

[80]  S. Yalkowsky,et al.  Systemic absorption of insulin from a Gelfoam ocular device. , 1999, International journal of pharmaceutics.

[81]  J. Born,et al.  Intranasal Insulin Improves Memory in Humans: Superiority of Insulin Aspart , 2007, Neuropsychopharmacology.

[82]  M. Mihic,et al.  The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist™ System , 2002, Diabetes/metabolism research and reviews.

[83]  S. Mitragotri,et al.  Current status and future potential of transdermal drug delivery , 2004, Nature Reviews Drug Discovery.

[84]  S. Clement,et al.  Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. , 2004, Metabolism: clinical and experimental.

[85]  G. Slama,et al.  PREPRANDIAL INTRANASAL INSULIN AS ADJUVANT THERAPY IN TYPE II DIABETICS , 1987, The Lancet.

[86]  L. Heinemann,et al.  Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. , 2002, Diabetes care.

[87]  J. Bluestone,et al.  Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. , 2006, The Journal of clinical investigation.

[88]  Selcan Türker,et al.  Nasal route and drug delivery systems , 2004, Pharmacy World and Science.

[89]  P. Wertz,et al.  Drug delivery via the buccal mucosa , 1998 .

[90]  Y. Chien,et al.  Systemic delivery of peptides and proteins across absorptive mucosae. , 1996, Critical reviews in therapeutic drug carrier systems.

[91]  A. Himmelmann,et al.  The impact of smoking on inhaled insulin. , 2003, Diabetes care.

[92]  G. Cevc Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. , 1996, Critical reviews in therapeutic drug carrier systems.

[93]  T. Heise,et al.  The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. , 2005, Diabetes care.

[94]  S. Jain,et al.  Transfersomes—A Novel Vesicular Carrier for Enhanced Transdermal Delivery: Development, Characterization, and Performance Evaluation , 2003, Drug development and industrial pharmacy.

[95]  L. Heinemann,et al.  Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. , 2005, Diabetes care.

[96]  T. Stanley,et al.  An in vivo dog model for studying recovery kinetics of the buccal mucosa permeation barrier after exposure to permeation enhancers: apparent evidence of effective enhancement without tissue damage , 1994 .

[97]  V. Lassmann-Vague,et al.  PREPRANDIAL INTRANASAL INSULIN , 1988, The Lancet.

[98]  B. Zinman,et al.  Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes , 2005, Annals of Internal Medicine.

[99]  F. Plakogiannis,et al.  Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and alpha-tocopherol dispersions. , 2002, International journal of pharmaceutics.

[100]  H. Schulz Mechanisms and factors affecting intrapulmonary particle deposition: implications for efficient inhalation therapies Holger Schulz , 1998 .

[101]  S. Mudaliar,et al.  Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. , 2003, Diabetes care.

[102]  P. Pozzilli,et al.  Biokinetics of buccal spray insulin in patients with type 1 diabetes. , 2005, Metabolism: clinical and experimental.

[103]  G. Chiou,et al.  Alternative delivery of insulin via eye drops. , 2005, Diabetes technology & therapeutics.

[104]  R. Guy,et al.  Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. , 1998, Journal of controlled release : official journal of the Controlled Release Society.